Compare MAR & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAR | GSK |
|---|---|---|
| Founded | 1927 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | 66841 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9B | 108.7B |
| IPO Year | 2005 | N/A |
| Metric | MAR | GSK |
|---|---|---|
| Price | $354.61 | $50.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | ★ $359.31 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 3.9M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | 0.76% | ★ 3.40% |
| EPS Growth | ★ 14.17 | N/A |
| EPS | ★ 9.51 | N/A |
| Revenue | ★ $26,186,000,000.00 | N/A |
| Revenue This Year | $304.38 | $6.99 |
| Revenue Next Year | $5.38 | $4.19 |
| P/E Ratio | $36.45 | ★ $32.75 |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $250.79 | $35.45 |
| 52 Week High | $380.00 | $61.70 |
| Indicator | MAR | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 30.65 |
| Support Level | $312.30 | $47.89 |
| Resistance Level | $370.00 | $51.46 |
| Average True Range (ATR) | 8.24 | 0.88 |
| MACD | -2.78 | -0.70 |
| Stochastic Oscillator | 29.53 | 5.86 |
Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.